Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket.